Development and characterization of injectable depot forming thermoresponsive hydrogel for the sustained intrascleral delivery of Sunitinib

Age-related macular degeneration (AMD) is a potentially blinding posterior segment disease; inflammatory responses and subretinal drusen formation lead to leaky blood vessels. The current treatment method involves intravitreal injections of anti-VEGF agents, which highly invasive requires frequent administered by trained personnel. Periocular such as trans-/intra-scleral would provide minimally option. sclera the outermost protective layer occupying 5/6th ocular globe. Owing its avascular nature self-healing ability, could be potential space for delivery depot forming long-acting formulations. This project focuses on development chitosan grafted poly(n-isopropylacrylamide) (Cs-g-PNIPAAm) gel sustained intrascleral small molecular weight, multiple tyrosine kinase inhibitor Sunitinib malate.